London surgeons remove pituitary tumour in first operation using real-time AI assistance
Science & ClimateWell-covered
|
The Facts
- Surgeons at the National Hospital for Neurology and Neurosurgery, part of University College London Hospitals, removed a pituitary tumour from Rhys Hibbert, 48.
- UCLH says it was the world's first brain tumour operation carried out with real-time artificial intelligence support.
- The AI system analysed a live video feed from the operation and colour-coded critical structures such as nerves, blood vessels and the pituitary gland.
- The surgical team retained full control of the procedure, with the software only flagging areas to avoid.
- The tumour measured about 11mm and was non-cancerous.
- Surgeons said Hibbert risked losing his sight without the operation because the tumour was pressing near his optic nerves.
- The operation took place in May.
- The hospital had used the technology as a research tool for some time, and the May operation was its first use on a patient.
- Hibbert says the operation saved his sight and he has returned to work as a customer services manager.
Context
Why is surgery on the pituitary gland considered high-risk?
The pituitary gland sits at the base of the skull in an area where blood vessels and the nerves controlling vision are tightly packed together; medics said "going a millimetre wrong can make a critical difference" Manchester Evening …. Russian coverage of the hospital's account noted that an error of a millimetre in this region could result in loss of vision, stroke or death Московский …,Life.ru.
How did Hibbert's tumour come to be found?
Hibbert, a father of two from Bedfordshire, was fit and healthy until he collapsed and had a seizure during one of his regular lunchtime walks BBC,En Son Haber,CNN Türk. Scans then found the tumour on his pituitary gland; Euronews reports he was diagnosed in December 2024 Euronews English,En Son Haber.
Is the tool available to other patients?
The system was developed at University College London and had previously been used by the hospital only as a research tool Sputnik Азе…,Independent,RTE.ie. Hibbert volunteered to take part in the research, saying: "If patients are not prepared to join research how can doctors ever learn and how can medicine ever progress?" Euronews English. The available sources do not set out a timetable for wider clinical use.
Where Left and Right agree, and where they split
Left and right largely agree on this one.
- Where Left and Right agree
- Both read the same design as correct: the software only colour-coded nerves and vessels while surgeons kept full control, and both want that model to continue.
- Where Left and Right differ in emphasis
- Both endorse surgeon-directed AI; one because a man risking his sight cannot be an experiment, the other because the tool armed rather than displaced judgement.
- Why they won’t converge
- This is a burden-of-proof divide, not a factual one: both sides accept the same single good outcome, but disagree over who must prove what before the next patient, so one success reads either as caution vindicated or caution outgrown.
How left and right read it
A publicly funded hospital, not a product launch, is where this belongs: the technology sat as a research tool for some time before it ever touched a patient, and even then the software only flagged nerves, vessels and the pituitary gland for surgeons who kept full control. That order of proof matters. Because a man facing the loss of his sight cannot be an experiment, the burden stays on the system to earn each step toward the operating table — human judgement first, always.
“While the surgical team remained in full control, the AI system analysed live camera footage during the operation, helping identify key structures such as nerves and blood vessels that should be avoided” — The Guardian
A tool that sharpens a surgeon's eye without taking his hand off the instrument is exactly the kind of innovation worth defending, because the software here only colour-coded nerves, vessels and the pituitary gland while the team kept full control of the procedure. Human judgement was never displaced; it was armed. And a 48-year-old man facing the loss of his sight kept it. Let capability like this advance — clinician-directed, and proven in the doing.
The receipts — all 48 sources
Independent coverage (48)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.